Non-Fucosylated Anti-Human ACVRL1 (ActRIIa-mFc) Therapeutic Antibody (CAT#: BioBet-515ZP) Datasheet

ACVRL1

activin A receptor type II-like 1

This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hemorrhagic telangiectasia type 2, also known as Rendu-Osler-Weber syndrome 2.

ACVRL1; activin A receptor type II-like 1; HHT; ALK1; HHT2; ORW2; SKR3; ALK-1; TSR-I; ACVRLK

Plasma membrane

Diseases associated with ACVRL1 include Telangiectasia, Hereditary Hemorrhagic, Type 2 and Pulmonary Hypertension, Primary, 1.

Its related pathways are Akt Signaling and PEDF Induced Signaling.

Type I receptors of TGF-β family ligands BMP9/GDF2 and BMP10 and important regulators of normal vascular development. After the ligand binds, a receptor complex composed of two type II and two type I transmembrane serine/threonine kinases is formed. Type II receptors phosphorylate and activate type I receptors, which automatically phosphorylate and then bind and activate SMAD transcriptional regulators. It can also be combined with activin.

Cell Biology and Cellular Response antibody; Metabolism antibody; Signaling Transduction antibody

1.Glycosylation at Asn98 2.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

ActRIIa-mFc

Human

Human

ADCC-Enhanced anti-ACVRL1 (ActRIIa-mFc) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.

Urothelial Cancer

Urothelial Cancer